Trial Profile
Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 25 Jan 2023 Status changed from active, no longer recruiting to completed.
- 06 Apr 2022 Planned End Date changed from 6 Apr 2022 to 6 Apr 2023.
- 18 Mar 2021 Planned End Date changed from 6 Apr 2021 to 6 Apr 2022.